

**ondine**



**For Immediate Release**

**ONDINE ANNOUNCES PERIOWAVE PRESENTATION AT IADR ANNUAL MEETING**

**Vancouver, Canada – July 2, 2008** - Ondine Biopharma Corporation (TSX: OBP; AIM: OBP), a medical technology company developing photodisinfection-based products, today announced that data from a study evaluating its Periowave Photodynamic Disinfection System will be presented at the International Association for Dental Research (IADR) 86<sup>th</sup> General Session & Exhibition in Toronto, Ontario on Thursday, July 3, 2008.

A poster presentation, entitled, “*In vitro* Bactericidal Efficacy of Periowave Photodynamic Disinfection System”, based on research conducted by Loma Linda University School of Dentistry (Loma Linda, California), will be presented on Thursday, July 3, 2008 from 3:30 pm to 4:45 pm (Metro Toronto Convention Centre Exhibit Hall D-E, abstract 1281).

“Periowave™ was used in this study to eradicate Gram-negative bacteria including *E. faecalis*, which can be difficult to kill even using bleach disinfection” stated Dr. Nicolas Loebel, Ondine’s Chief Technology Officer. “The bacteria are unaffected by the light or the photosensitizer when used alone. When exposed to the Periowave™ Photodisinfection System, these virulent pathogens are completely eliminated within 60 seconds. Because Periowave™ works so differently to antibiotics, it does not increase bacterial resistance - an important advantage as more and more bacteria develop immunity to the conventional agents used today. Periowave™ provides the practitioner with a non-antibiotic alternative that has been proven safe and effective in clinical practice, eradicating bacteria associated with many different disease processes.”

Further details on the abstract are available at:

[http://iadr.confex.com/iadr/2008Toronto/techprogram/abstract\\_108006.htm](http://iadr.confex.com/iadr/2008Toronto/techprogram/abstract_108006.htm)

**About Periowave™**

Periowave™ is a photodisinfection system commercialized by Ondine that utilizes low-intensity lasers and microbiological stains to target and destroy microbial pathogens and reduce the symptoms of disease. The photodisinfection technology was developed by Professor Michael Wilson and colleagues at the Eastman Dental Institute, University College London, and licensed to Ondine by UCL Business plc, University College London. Periowave™ is currently approved in Canada and the European Union for several oral indications. Additional information about Periowave™ is available at [www.periowave.com](http://www.periowave.com)

## **About Ondine Biopharma Corporation**

Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on developing and commercializing leading edge products utilizing its patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada, with a research laboratory in Bothell, Washington, and an international office in St Michael, Barbados. For additional information, please visit the Company's website at: [www.ondinebiopharma.com](http://www.ondinebiopharma.com)

### **Forward-Looking Statements:**

*Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products and other risk factors identified from time to time in the Company's filings.*

The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

### **FOR FURTHER INFORMATION please contact:**

Carolyn Cross  
President and  
Chief Executive Officer  
Ondine Biopharma Corporation  
(604) 669-0555  
ccross@ondinebiopharma.com

Christina Bessant  
/ Adam Peeler  
Investor Relations  
The Equicom Group Inc.  
(416) 815-0700 ext. 269  
cbessant@equicomgroup.com

Canaccord Adams Ltd  
Nominated Adviser &  
Broker  
Neil Johnson /  
Ryan Gaffney  
+4420 7050 6500